Court Sides with Cardiovalve in Edwards patent spat
HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve") against Edwards Lifesciences Corporation and Edwards Lifesciences LLC. ...
Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
HONG KONG, April 22, 2025 /PRNewswire/ -- Venus?MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year endedDecember 31, 2024 ("the Year"), demonstratin...
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK),?a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced?that its in-house developed next-generation balloon-expandable dry-tissue tra...
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
HANGZHOU, China, June 14, 2024 /PRNewswire/ -- Venus Medtech?(02500. HK),?a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced?today that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, Venus...
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus?Medtech (02500. HK),?a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced today?that, VenusP-Valve, the company's in-house developed innovative transcatheter pulmonic valve replaceme...
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Venus Medtech is changing how the world treats structural heart disease. The com...
VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally
HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Recently, Venus?Medtech (Hangzhou ) Inc. ("Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced the Investigational Device Exemption (IDE) full approval for its in-house de...
Confirmatory clinical trial of Liwen RF? ablation system in China concluded
HANGZHOU, China, March 6, 2023 /PRNewswire/ -- On March 3, Venus Medtech ( Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the Liwen RF? ablation system developed by the Company has successfully enrolled one patient at West China Hospita...
Venus Medtech to showcase its structural heart treatments at London Valves 2022
The company's growing number of solutions for structural heart disease will be presented at multiple events during the conference betweenNovember 27-29 HANGZHOU, China, Nov. 25, 2022 /PRNewswire/ -- Venus Medtech is building an exciting pipeline of treatments?for structural heart disease. The co...
Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence
HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ --?On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced its interim results for the s...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
SHANGHAI, July 11, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totalingUS$3.2 billion, including USD Fund VIII atUS$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversub...
First American Patient Treated with VenusP-Valve? Under Compassionate Use
HANGZHOU, China, June 22, 2022 /PRNewswire/ -- VenusP-Valve?, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use atUniversity of Virginia Advanced Cardiac Valve Center in...
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
SHANGHAI, April 13, 2022 /PRNewswire/?– Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, andDuane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list. Since ...
Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide
HANGZHOU, China, April 1, 2022 /PRNewswire/ -- On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies inChina, announced its annual results for the yea...
Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18th, 2022, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 2500.HK), a leading provider of integrated solutions for structural heart disease inChina, announced the appointment ofShakeel Osman as Senior Vice President of Sales Europe, resp...
Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral a...
Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement
HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatm...
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
HANGZHOU, China, July 28, 2021 /PRNewswire/ --?On July 27, 2021, Venus Medtech ( Hangzhou) Inc.?("Venus Medtech")?(stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions inChina, and its controlling subsidiary Renaly Ltd., announced that Professor...
